Products
Online Inquiry
AGI-5198
Cat. No.:
OB0225WX-2672
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
AGI-5198 is a highly specialized inhibitor targeting the IDH1 R132H and R132C mutants, featuring IC50 values of 0.07 microM and 0.16 microM, respectively.
Synonym:
IDH-C35; 1355326-35-0; N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide; AGI-5198(IDH C35); N-cyclohexyl-2-(3-fluoro-N-[2-(2-methylimidazol-1-yl)acetyl]anilino)-2-(2-methylphenyl)acetamide; N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-o-tolylacetamide; AGI 5198; MFCD24848688; AGI-5198 (IDH-C35)
CAS No.:
1355326-35-0
Compound CID:
56645356
Formula:
C27H31FN4O2
Formula Weight:
462.56
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
AGI-5198 is applied in epigenetic research as a selective inhibitor of the mutant IDH1 R132H enzyme to study the reduction of oncometabolite 2-hydroxyglutarate levels and the reversal of epigenetic reprogramming.
Library Information
Target:
Dehydrogenase
Receptor:
IDH1
Pathways:
Metabolism
Plate Number:
L6700-08
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
24 mg/mL; 51.89 mM
Ethanol Max Solubility:
14 mg/mL
ALogP:
4.354
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
7
